From Free Rider to Innovator: The Rise of China's Drug Development | NBER
Founded in 1920, the NBER is a private, non-profit, non-partisan organization dedicated to conducting economic research and to disseminating research findings among academics, public policy makers, and business professionals.
From Free Rider to Innovator: The Rise of China's Drug Development | NBER Skip to main content From Free Rider to Innovator: The Rise of China's Drug Development Panle Jia Barwick , Hongyuan Xia & Tianli Xia Share X LinkedIn Facebook Bluesky Threads Email Link Working Paper 34977 DOI 10.3386/w34977 Issue Date March 2026 This paper examines China’s transition from pharmaceutical “free rider” to global innovator over the last decade. In 2010, China accounted for less than 8% of global clinical trials; by 2020, it had surpassed the US in annual registered clinical trial volume. To study
Explore this link on the map →related reading
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- Will all our drugs come from China? | Alex’s blogatelfo.github.io
- The rise and fall of the industrial R&D lab - Works in Progress Magazineworksinprogress.co
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Checking your browser - reCAPTCHAncbi.nlm.nih.gov
- Nature's drug database - The Works in Progress Newsletterworksinprogress.news
- Eroom's law - Wikipediaen.wikipedia.org
- The 23andMe Deal - Cremieux Recueilcremieux.xyz
- Why fixing the IRA matters to all of us - RApportrapport.bio
- Some questions about biotech that I find interesting | Alex’s blogatelfo.github.io
- Why the FDA Is Slow to Remove Drugspress.asimov.com
- Curious cases of financial engineering in biotechowlposting.com